Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-α-308GG genotype

Journal of Physiology and Biochemistry

Volumn 66, Issue 2, 2010, Pages 173-180

  Basic, Jelena ^a   Pavlovic, Dusica ^a   Jevtovic Stoimenov, Tatjana ^a   Vojinovic, Jelena ^b   Susic, Gordana ^c   Stojanovic, Ivana ^a   Kocic, Gordana ^a   Milosevic, Vuk ^b   Cvetkovic, Tatjana ^a   Marinkovic, Milena ^a   Veljkovic, Andrej ^a  

^a UNIVERSITY OF NI   (Serbia)

^b Clinical Centre Nis   (Serbia)

^c INSTITUTE OF RHEUMATOLOGY   (Serbia)

Author keywords

Etanercept; Juvenile idiopathic arthritis; MMP 9; TNF 308 polymorphism

Indexed keywords

ETANERCEPT; GELATINASE B; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; MALE; MATRIX METALLOPROTEINASE 9; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955095454     PISSN: 11387548     EISSN: 18778755     Source Type: Journal    
DOI: 10.1007/s13105-010-0022-x     Document Type: Article

References (35)

1. Allen RD (1999) Polymorphism of the human TNF-alpha promoter-random variation or functional diversity? Mol Immunol 36:1017-1027.
2. Bouma G, Crusius JBA, Pool O et al (1996) Secretion of tumour necrosis factor and lymphotoxin in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 43:456-463.
3. Chang YH, Lin IL, Tsay GJ et al (2008) Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Biochem 41:955-959.
4. Chen R, Fang M, Cai Q et al (2007) Tumor necrosis factor alpha- 308 polymorphism is associated with rheumatoid arthritis in Han population of Eastern China. Rheumatol Int 28:121-126.
5. Choy EHS, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916.
6. Cimaz R, Cazalis MA, Reynaud C et al (2007) IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann Rheum Dis 66:900-904.
7. Cordiali-Fei P, Trento E, D'Agosto G et al (2007) Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann NY Acad Sci 1110:578-589.
8. Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D (1995) Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 12:127-133.
9. Date Y, Seki N, Kamizono S et al (1999) Basic science-identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFa gene and HLA genes-this report describes the allele. Arthritis Rheum 42:2577-2582.
10. De Benedetti F, Pignatti P, Gerloni V, Massa M, Sartirana P, Caporali R (1997) Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 24:1403-1407.
11. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Silva WA Jr, Tanus-Santos JE (2008) Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med 46:57-63.
12. Fiedorczyk M, Klimiuk PA, Sierakowski S, Gindzienska-Sieskiewicz E, Chwiecko J (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol 33:1523-1529.
13. Gattorno M, Picco P, Buoncompagni A et al (1996) Serum p 55 and p 75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis 55:243-247.
14. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40:1202-1209.
15. Gruber BL, Sorbi D, French DL et al (1996) Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 78:161-171.
16. Kim JH, Jeong JH, Jeon ST et al (2006) Decursin inhibits induction of inflammatory mediators by blocking nuclear factor-{kappa} B activation in macrophages. Mol Pharmacol 69:1783-1790.
17. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J (2002) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology 41:78-87.
18. Lianxu C, Hongti J, Changlong Y (2006) NF-Bp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1beta-induced and TNF-alpha-induced chondrocytes. Osteoarthritis Cartilage 14:367-376.
19. Louis E, Franchimont D, Piron A et al (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113:401-406.
20. Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763-769.
21. Mangge H, Gallist S, Schauenstein K (1999) Long-term follow-up of cytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis. J Interferon Cytokine Res 19:1005-1010.
22. Martínez A, Fernández-Arquero M, Pascual-Salcedo D et al (2000) Primary association of tumor necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis. Arthritis Rheum 43:1366-1370.
23. Ozen S, Alikasifoglu M, Bakkaloglu A et al (2002) Tumour necrosis factor alpha G- > A-238 and G- > A-308 polymorphisms in juvenile idiopathic arthritis. Rheumatology 41:223-227.
24. Peake NJ, Foster HE, Khawaja K, Cawston TE, Rowan AD (2006) Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography. Ann Rheum Dis 65:501-507.
25. Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390-392.
26. Rodríguez-Carreón AA, Zúñiga J, Hernández-Pacheco G et al (2005) Tumor necrosis factor-alpha-308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in Mexicans. J Autoimmun 24:63-68.
27. Rood MJ, van Krugten MV, Zanelli E et al (2000) TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum 43:129-134.
28. Rooney M, Varsani H, Martin K, Lombard PR, Dayer JM, Woo P (2000) Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis. Rheumatology 39:432- 438.
29. Sandya S, Achan MA, Sudhakaran PR (2009) Multiple matrix metalloproteinases in type II collagen induced arthritis. Indian J Clin Biochem 24:42-48.
30. Schmeling H, Wagner U, Peterson A, Horneff G (2006) Tumor necrosis factor alpha promoter polymorphisms in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 24:103-108.
31. Schmeling H, Horneff G (2007) Tumor necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. Rheumatol Int 27:383- 386.
32. Tchetverikov I, Ronday HK, Van El B et al (2004) MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Br Med J 63:881-883.
33. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW (1997) Effects of a polymorphism in the human tumor necrosis factor promoter on transcriptional activation. Proc Natl Acad Sci USA 94:3195-3199.
34. Xue M, March L, Sambrook PN, Jackson CJ (2007) Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis. Arthritis Rheum 56:2864-2874.
35. Yen JH, Chen CJ, Tsai WC et al (2001) Tumor necrosis factor promoter polymorphisms in patients with rheumatoid arthritis in Taiwan. J Rheumatol 28:1788-1792.